Crescent Capital BDC posted strong Q2 income and dividend coverage, yet trades at a steep 21% NAV discount despite solid ...

Eldorado's stock has performed exceptionally well this year, rising more than 50% on the back of gold's momentum and Skouries ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Afya's Q2 2025 results were solid, but the stock faces headwinds from market saturation and regulatory changes in Brazil's ...

BP delivered strong Q2 results, beating earnings and revenue estimates due to strong profitability in its core business.

Cencora (COR) directors agrees to a $111M cash payment to resolve claims by pension funds that their policies were inadequate ...

T-Mobile debuts investment-grade baby bonds (TMUSZ, TMUSL, TMUSI) maturing 2069–2070. Explore yields up to 6.22% and strong ...

The real assets portfolio was the primary detractor due to negative returns for energy stocks and U.S. real estate investment ...

Tonix's Tonmya received FDA approval, marking the first new fibromyalgia therapy in 15 years and driving a post-market stock ...

Downgrading Banco do Brasil to underperform after consecutive weak quarters, driven by surging defaults in agribusiness and ...

IHF offers exposure to large-cap healthcare, AI-driven growth, and demographic trends, with a recent dip creating a strong ...

Novo Nordisk (NVO) stock in focus as the company wins FDA accelerated nod for weight loss therapy Wegovy against the liver ...